Responses
Rheumatoid arthritis
Original research
Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)
Compose a Response to This Article
Other responses
No responses have been published for this article.